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Abstract
Due to improvements in the number of cancer survivors and survival time, there is a growing interest in healthy behaviors, 
such as physical activity (PA), and their potential impact on cancer- and non-cancer-related morbidity in individuals with 
cancer. Commissioned by the Spanish Society of Medical Oncology (SEOM), in this review, we sought to distill the most 
recent evidence on this topic, focusing on the mechanisms that underpin the effects of PA on cancer, the role of PA in cancer 
prevention and in the prognosis of cancer and practical recommendations for clinicians regarding PA counseling. Despite 
the available information, the introduction of exercise programs into the global management of cancer patients remains a 
challenge with several areas of uncertainty. Among others, the most effective behavioral interventions to achieve long-term 
changes in a patient’s lifestyle and the optimal intensity and duration of PA should be defined with more precision in future 
studies.
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Introduction
Regular and adequate physical activity (PA) is associated 
with key benefits to human health, such as improvements in 
weight control, muscular and cardiorespiratory fitness, bone 
and functional health and a reduced risk of falls and several 
noncommunicable diseases, including diabetes, cardiovas-
cular disease, depression and some cancers [1].
Due to improvements in the management of cancer, the 
number of cancer survivors and survival time are increas-
ing. Consequently, interest in healthy behaviors, such as PA, 
and their potential impact on cancer- and non-cancer-related 
morbidity in these individuals has rapidly increased [2].
Commissioned by the Spanish Society of Medical Oncol-
ogy (SEOM), in this review, we sought to distill the most M. Pollán and S. Casla-Barrio have equally contributed to this 
work.
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recent evidence on this topic, focusing on the mechanisms 
that underpin the effects of PA on cancer, describing the 
role of PA in cancer prevention and prognosis, and provid-
ing practical recommendations to clinicians on managing 
PA counseling.
Biological mechanisms underpinning 
the potential anticancer effects of exercise
Of note, PA is any bodily movement produced by skeletal 
muscles that requires energy expenditure, whereas exercise 
is a subset of PA that is planned, structured and repetitive 
and that has a final or an intermediate objective of improv-
ing or maintaining physical fitness. The epidemiological 
evidence regarding the risk of some cancers mainly refers 
to regular PA (usually self-reported, i.e., through question-
naires). Thus, regular exercise or “exercise training” is a 
proxy, but not a perfect surrogate, for PA and is thought to 
induce more profound molecular adaptations than PA.
There is growing evidence from preclinical research that 
regular exercise can influence cancer development or the rate 
of tumor growth once malignancy has initiated. For instance, 
a recent meta-analysis of 28 preclinical studies in breast 
tumors (n = 2085 animals) found large favorable effects for 
exercise training on proliferation and apoptosis [3]. Exercise 
is also emerging as a potential coadjuvant treatment; when 
combined with cyclophosphamide, exercise delays murine 
breast tumor growth versus chemotherapy alone [4], and 
similar findings have been reported for exercise combined 
with anthracyclines [5–7]. There is, however, heterogeneity 
among studies in the tumor models used, ranging from tumor 
transplant (where there is also substantial variability, e.g., 
syngeneic versus xenograft models) to carcinogen-induced 
or genetically engineered mouse models [8]. The type of 
exercise training to which mice are typically subjected to 
before/upon tumor inoculation also varies between studies 
(forced treadmill, forced swimming, voluntary wheel run-
ning). The duration of exercise in the trials typically consists 
of several weeks (~ 4 to 10 weeks), which can be translated 
to human “years.”
Exercise can have an impact on tumor development, 
growth or dissemination through several mechanisms. First, 
exercise might help to prevent cancer by reducing the cir-
culating levels of several mediators, such as insulin growth 
factor-1 (IGF-1) [9–14], a mitogen that triggers cell prolif-
eration [15]. Exercise can also reduce the levels of hyper-
phosphorylated retinoblastoma protein (Rb) in a chemically 
induced rat model of mammary carcinogenesis [16, 17], 
increase ß-catenin phosphorylation in colon polyps [18, 19], 
and reduce the levels of micro-RNA 21 [20].
Exercise can upregulate tumor suppressors, such as the 
tumor suppressor programmed cell death protein 4 in a 
murine model of estrogen receptor-positive breast cancer 
(BC) [21]. In addition, exercise-induced catecholamines 
might reduce BC development through activation of the 
Hippo tumor suppressor pathway [22] and exercise-induced 
increased p53 activation, leading to tumor prevention, as 
shown in mouse models of skin [13, 23] and lung [24] 
cancer.
Exercise training can stimulate apoptosis, as shown in 
xenograft models of lung adenocarcinoma [24] and human 
pancreatic and prostate cancers [25, 26] and in murine mod-
els of skin tumorigenesis [12] and mammary carcinoma [4, 
16, 27]. Exercise also exerts proapoptotic effects on cul-
tured prostate cancer cells [28], estrogen receptor-positive 
BC cells [29, 30] and lymph node metastases of prostate 
tumor cells [25]. Exercise additionally reduces the levels 
of the antiapoptotic protein B cell lymphoma 2 [16, 31] and 
stimulates the proapoptotic proteins Bax and Bak [4, 16, 24] 
and the protein kinase AMPK [32, 33].
Hypoxia and poor blood supply promote an aggressive 
cancer phenotype and contribute to ineffective systemic 
therapy [34]. In this respect, exercise may promote a shift 
toward a more “normalized” tumor microenvironment by 
improving intratumoral perfusion/vascularization, at least in 
orthotopic murine models of human BC [4, 35] and prostate 
cancer [36–38] and in xenografts of different tumors (mela-
noma, pancreas) [39].
Exercise might also attenuate the development of metas-
tases. Mouse exercise training can decrease catenin while 
increasing E-cadherin inside tumors [19, 40]. Importantly, 
cadherins act as glue between epithelial cells, and their 
loss can favor malignancy by allowing the disaggregation 
of cells, which can then invade locally or metastasize [40]. 
Moderate-intensity mouse swimming can suppress liver can-
cer metastases via boosting the activity of dopamine recep-
tor 2 [40]. Exercise may also modulate blood–brain barrier 
integrity by maintaining the expression levels of occludin or 
claudin-5 proteins [41], thereby preventing metastatic pro-
gression to the brain [42]. On the other hand, inflammatory 
cells within the tumor microenvironment supply bioactive 
molecules that sustain cancer hallmarks [43–45]. In this con-
text, mouse exercise training decreases macrophage infiltra-
tion in allogeneic lymphoid tumors [46], Ehrlich tumor cells 
[47] and colon polyps [18].
One major potential “anticancer” effect of exercise lies in 
an enhancement of immune function [43, 48]. At moderate 
intensities, exercise can stimulate the innate immune sys-
tem, especially natural killer (NK) cells [49, 50]. A 6-week 
mouse wheel running program had preventive effects against 
the development of several types of tumors (melanoma, liver 
and lung cancers), and the effect was mediated by improved 
NK cell infiltration into the tumors, which in turn was medi-
ated by the enhanced tumor expression of ligands for several 
NK cell-activating receptors [51]. A previous study showed 
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that exercise training increased the cytolytic capacity of resi-
dent peritoneal macrophages against mastocytoma cells [52]. 
Mouse exercise training could also polarize the immuno-
logical response toward an efficient “antitumor” macrophage 
profile 1, which is linked to the production of T-helper 1 
cytokines [52–56]. Short-term (6-day) moderate exercise 
before the injection of melanoma cells into mice decreased 
their metastatic spread, which was partially mediated by 
increased antitumor macrophage cytotoxicity [57]. Prelimi-
nary data from mice [53, 58–60] and cancer patients suggest 
that exercise training may help to reduce the immunosup-
pressive effects of T regulatory lymphocytes [61]. Finally, 
regular exercise can increase alveolar macrophage antitumor 
cytotoxicity in vitro, which would mediate a protective effect 
against mouse lung metastases [62, 63].
Importantly, skeletal muscle, especially during contrac-
tions, releases molecules collectively known as “myokines” 
into the bloodstream, which act systemically to induce 
a myriad of health-promoting effects, such as decreased 
inflammation and reduced insulin resistance [64]. Some 
myokines might also induce direct anticancer effects (via the 
stimulation of apoptosis in tumor cells), such as oncostatin 
M in hormone-sensitive BC [30] or secreted protein acidic 
and rich in cysteine (SPARC, also known as osteonectin) 
in colon cancer [65]. The aforementioned exercise-induced 
infiltration of NK cells into tumors seems to be mediated by 
the release of interleukin 6 by muscle into the bloodstream 
[49, 51, 66].
Physical activity and cancer prevention
According to the World Health Organization (WHO), up to 
31% of the adult population worldwide and 35% in Europe 
are physically inactive [67]. PA is difficult to measure for 
the following reasons: (1) there are at least four domains: 
occupational, household, transportation and leisure time; (2) 
PA questionnaires on past and current activity are subject to 
recall bias; and (3) objective methods (pedometers or accel-
erometers) can only be used in prospective studies for short 
time periods, and they may not always represent overall PA. 
Fortunately, smartphones and other devices now allow PA 
monitoring and will hopefully provide more accurate meas-
ures in the future.
Body mass is related to PA and cancer risk, acting as a 
confounder. However, the prevention of adiposity may medi-
ate the relationship between PA and cancer, and controlling 
for adiposity could lead to underestimating the real effect 
of PA [68].
Of note, 1 metabolic equivalent (MET) is the rate of 
energy expenditure while resting or 3.5 ml  O2/kg body 
weight/min on average. Moderate PA (e.g., brisk walking) 
usually requires an energy expenditure of 3–6 MET, whereas 
vigorous PA (e.g., jogging) requires an energy expenditure 
above 6 MET. The WHO recommends that adults engage 
in ≥ 150 min/week of moderate PA or ≥ 75 min/week of vig-
orous PA or a combination thereof. If a person does an ~ 3 
MET activity (e.g., brisk walking on a level surface) for 1 h, 
he or she has done 3 MET-hours of PA. If this person does 
this same PA on every day of the week, he/she has done 
21 (= 3 × 7) MET-hours/week. If a person does an ~ 8 MET 
activity (e.g., jogging) for 1 h on each day of the week, he/
she has done 56 (= 8 × 7) MET-hours/week.
The World Cancer Research Fund and the American Insti-
tute for Cancer Research periodically publish the conclu-
sions of a panel reviewing evidence linking food, nutrition 
and PA with cancer risk [69]. The evidence is classified as 
follows: (1) convincing: available results support a causal 
relationship; (2) probable: evidence supports a probable 
causal relationship; and (3) limited: results are not con-
sidered sufficient to rate the relationship as convincing or 
probable. In the last category, a distinction is made between 
limited-suggestive evidence when an effect is reported but 
there were methodological problems and limited-not conclu-
sive evidence when there were insufficient data and/or the 
results were too heterogeneous. The panel concluded that 
regular, sustained PA protects against several types of cancer 
independent of body fat [69]. This evidence comes from 
high-income countries and is mainly based on leisure-time 
PA. The three tumors with the most solid results are colon, 
postmenopausal BC and endometrial.
Colorectal cancer
The evidence for colon cancer is judged as “convincing,” 
with an overall risk reduction of approximately 20% in the 
most physically active group compared with the less active 
group [70]. The effect is weaker or absent for rectal cancer. 
However, a pooled analysis of 12 prospective cohort stud-
ies with information on leisure-time PA at baseline com-
pared the group at the 90th percentile of PA with the group 
under the 10th percentile and showed a reduced incidence 
of both colon (13% reduction) and rectal cancer (12%) after 
controlling for body mass index (BMI) [71]. Regarding 
the amount of PA required to obtain maximum benefit, a 
cohort of more than 40,000 men in the USA (The Health 
Professionals Follow-up Study) showed that aerobic PA 
seems to be more beneficial and that overall PA is more rel-
evant than the intensity of PA [72]. Finally, while a benefit 
was observed in men meeting current guidelines (17% risk 
reduction), the maximum benefit (32% risk reduction) was 
observed for PA ≥ 30 metabolic equivalents (MET)-hours/
week, which is equivalent to 10 h or more of walking/week 
[72]. A meta-analysis evaluating the dose–response shape of 
PA for different endpoints, including colon cancer, showed 
that major gains occurred at lower levels of activity (up to 
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50 MET-hours/week), while a decrease in risk was minimal 
at levels higher than 50–65 MET-hours/week [73].
Breast cancer
The evidence for postmenopausal BC is judged as “prob-
able” [74]. Most studies show a protective effect with a 
13% decreased risk in high versus low PA groups [74]. For 
recreational PA, a nonlinear dose–response was observed 
with a greater decrease in the risk for PA activity at > 20 
MET-hours/week [74]. The pooling analysis with informa-
tion on baseline leisure PA showed a reduction of 7% in the 
incidence of BC between the 90th and the 10th percentiles 
of PA [71]. Evidence for PA in premenopausal BC was rated 
as “limited-suggestive” for total PA and as “probable” for 
vigorous-intensity PA [74]. In Canada, a cohort study with 
39,000 women reported a clear downward trend of BC inci-
dence based on the number of MET-hours/week, which was 
mainly due to the risk reduction observed for premenopausal 
tumors [75]. Finally, a case–control study in Spain showed a 
reduced risk of 5% per 6 MET-hours/week [76]. The protec-
tion was particularly important for nulliparous women (12% 
risk reduction per 6 MET-hours/week) [76].
Endometrial cancer
The evidence for endometrial cancer was rated as “proba-
ble,” and the results showed a lower risk of endometrial can-
cer with higher levels of PA [77]. A meta-analysis reported 
a 20% risk reduction in high versus low PA groups [78]. 
This inverse association was only observed in overweight/
obese women [78]. The pooled analysis of PA at baseline in 
12 cohorts showed a risk reduction of 21% between the two 
extreme deciles of PA before taking BMI into account, while 
adjusting for BMI reduced the benefit to a nonsignificant risk 
reduction of 2% [71]. In the stratified analyses, PA was only 
associated with endometrial cancer in women with a BMI 
equal to or greater than 25 [71].
Lung cancer
A recent report classifies the evidence for lung cancer as 
“limited-suggestive” [69]. Leisure-time PA was considered 
in a systematic review, showing a clear inverse association 
with all histological lung cancer subtypes but only among 
former or current smokers [79]. The pooled analysis of 
cohort studies on leisure-time PA reported a 27% reduc-
tion in lung cancer incidence in the highest decile of PA 
compared with the lowest [71]. Again, the effect was only 
observed among smokers [71].
Liver cancer
The World Cancer Research Fund/American Institute 
for Cancer Research (WCRF/AICR) report classifies the 
evidence for liver cancer as “limited-suggestive” [80]. In 
the joint analysis of liver cancer incidence in 12 cohorts 
according to recreational PA at baseline, the highest decile 
had a hazard ratio (HR) of 0.73 before taking BMI into 
account and decreased to a nonsignificant HR of 0.81 
when BMI was included as a confounder [71].
Esophageal cancer
There is limited but suggestive evidence of a protective 
effect of PA against esophageal adenocarcinoma and squa-
mous cell carcinomas [81]. A meta-analysis found a risk 
ratio (RR) of 0.79 for esophageal adenocarcinoma and a 
nonsignificant RR of 0.94 for esophageal squamous cell 
carcinoma [82]. The pooled analyses of 1,44 million indi-
viduals from 12 cohorts showed an approximately 40% 
risk reduction in esophageal adenocarcinomas and a 24% 
risk reduction in esophageal squamous tumors for partici-
pants in the 90th percentile of leisure-time PA at baseline 
compared with the lowest PA group [71].
Stomach cancer
The recent WCRF/AICR update still considers limited-not 
conclusive evidence available for stomach cancer [83]. A 
previous meta-analysis on gastric cancer estimated an RR 
of 0.82 for high versus low PA [82]. The pooled analysis of 
leisure-time PA at baseline in the 12 cohorts showed a 22% 
risk reduction for gastric cardia tumors when BMI was not 
taken into account, but stratification by BMI showed that 
the protective effect was only observed among overweight/
obese people [71].
Prostate cancer
There is a limited-not conclusive evidence of a link 
between PA and prostate cancer [84]. A systematic review 
showed substantial heterogeneity among 85 studies: 22 
reported a statistically significant risk reduction, 25 
reported a nonsignificant risk reduction, 31 did not find 
any association, and eight found an adverse effect of PA 
[85]. A higher incidence of prostate cancer (4% increase) 
was observed among the 10% more physically active 
participants in the pooled analysis of 12 cohort studies 
compared with those with a lower decile of activity. The 
authors hypothesized that this result could be due to a 
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higher probability of prostate cancer screening in physi-
cally active men [71].
Ovarian cancer
The evidence for ovarian cancer was considered limited-
not conclusive [86]. While most case–control studies found 
significant risk reductions among very active women, most 
cohort studies failed to show a clear effect [87]. The pool-
ing analysis of 1.44 million participants in 12 prospective 
cohorts in the USA and Europe did not find a protective 
effect of high leisure-time PA for this tumor [71]. The 
Nurses’ Health Study, a prospective cohort with updated 
information on leisure-time PA, revealed an increased risk 
for both low and high levels of premenopausal PA, while no 
association was observed in postmenopausal women [88].
Pancreatic cancer
The WCRF/AICR report considers limited-not conclusive 
evidence for pancreatic cancer [89]. A meta-analysis yielded 
a statistically significant RR of 0.89 for high versus low PA 
[90]. Stronger effects were observed in case–control stud-
ies and for younger populations [90]. The pooling analysis 
of 12 cohort studies showed a non-statistically significant 
reduction of 5% in the most active group at baseline, but this 
effect was no longer observed when BMI was considered 
[71]. The EPIC-Norfolk cohort communicated a decreased 
risk in the highest category of total PA among participants 
younger than 60 years independent of BMI, while no effect 
was observed in older people [91].
Kidney cancer
The WCRF/AICR panel considers limited-not conclusive 
evidence for kidney cancer [92]; however, a meta-analysis 
in 2013 estimated a 12% risk reduction in the high PA group 
that was stronger when combining only high-quality studies 
[93]. The pooled analysis of the 12 cohorts showed a risk 
reduction of 16% independent of BMI among the most active 
group [71].
Bladder cancer
The evidence for bladder cancer is judged as limited-not 
conclusive [94]. A meta-analysis showed an RR of 0.85 for 
high versus low PA [95]. Moreover, the joint analysis of 
12 prospective cohorts found a significantly reduced risk 
of bladder tumors in participants for the highest decile of 
leisure-time PA at baseline (HR = 0.88) [71].
Other tumors
A systematic review and meta-analysis on PA and hemato-
logic cancers showed a reduced risk for non-Hodgkin lym-
phoma and nonsignificant results for multiple myeloma and 
leukemias [96]. The pooled analysis of 12 cohorts found a 
protective effect of PA against myeloid leukemia, myeloma 
and head–neck carcinomas [71]. Interestingly, malignant 
melanomas were more frequent in participants at the high-
est decile of leisure-time PA, a finding attributed to greater 
sun exposure due to outdoor activity and an increased risk 
of sunburn [71].
Summary and future directions
PA clearly reduces the risk of colon, BC and endometrial 
cancer. Furthermore, recent epidemiological studies suggest 
a protective effect for most cancer sites.
There is no conclusive evidence regarding the amount of 
PA needed to significantly reduce cancer risk, although it is 
likely tumor dependent.
New devices that routinely collect information on PA may 
help to increase the accuracy of PA measures and reduce 
information bias.
Effect of physical activity on the prognosis 
of cancer
Several reviews and meta-analyses of observational stud-
ies have suggested the benefit of PA on cancer outcomes. 
Most of the studies included breast cancer (Tables 1, 2) and 
colon cancer survivors (Table 3). A few studies have been 
conducted on patients with other types of neoplasms, such 
as prostate (Table 4), esophageal, lung and kidney cancer 
(Table 5). In these studies, PA is reported as lifetime PA 
in the latest years before or after diagnosis. The outcomes 
reported are usually overall survival, cancer-related survival, 
cancer recurrence and quality of life (QoL).
Epidemiologic and observational studies show a decrease 
in the risk of cancer recurrence and all-cause mortality in 
patients who practice regular PA [121–123]. A systematic 
review of studies published through June 2013 concluded 
that PA performed before or after cancer diagnosis is associ-
ated with a reduced mortality risk among BC and colorectal 
cancer survivors [124]. Mortality in adult survivors of child-
hood cancer was inferior in those patients who practiced 
vigorous exercise after diagnosis in a large multicentric 
observational study [125]. In 2015, Lahart et al. [97] pub-
lished a meta-analysis of 22 studies analyzing the impact 
of PA on BC outcomes. A literature search was performed 
using PubMed, EMBASE and CENTRAL databases from 
1995 to October 2014. In 40% of the observational studies, 
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the risk of relapse and death in BC survivors decreased in 
most physically active women. Most studies included an 
analysis of leisure-time PA and only a few of interventional 
PA programs. The majority of the studies did not perform 
a multivariable analysis to exclude the effect of known 
confounding factors, and less than half included clinical 
prognostic factors, such as stage, nodal status, age or type 
of treatment. These studies found a positive impact on all-
cause and BC mortality in patients who practiced moderate 
or intense lifetime PA before the diagnosis of BC and in 
recent years before diagnosis. However, the authors recom-
mend interpreting these results with caution due to the large 
heterogeneity of the studies. A post-diagnosis activity of at 
least 10 MET-hours/week was associated with a decrease 
in all-cause, and BC mortality and was not influenced by 
the heterogeneity; however, not all the studies could cor-
roborate a decrease in recurrence risk. The “After Breast 
Cancer Pooling Project” included more than 13,000 women 
from four prospective cohorts of BC survivors in the USA 
and Shanghai and analyzed the association between PA at 
18–48 months after diagnosis and risk of all-cause and BC-
specific mortality and BC recurrence [126]. BC mortality 
was reduced in patients who achieved 18.7 or more MET-
hours/week, and no association was found between PA and 
BC recurrence [126]. A comprehensive review of sixty-
three interventional studies on women after BC adjuvant 
therapy concluded that PA interventions might have certain 
beneficial effects on QoL, cardiorespiratory fitness and psy-
chological and social functions, but conclusions about BC 
recurrence, BC mortality and all-cause mortality could not 
be made [98].
Several prospective observational studies and meta-
analyses in patients with colorectal cancer have suggested 
the benefit of PA before and after diagnosis in terms of 
improvements on all-cause and cancer-specific mortality 
after controlling for other confounding factors, such as 
BMI, sex, number of positive lymph nodes, age, baseline 
performance status (PS), adjuvant chemotherapy regi-
men or recurrence-free survival period [110, 111, 127, 
128]. Similarly, three observational prospective stud-
ies in prostate cancer found a strong inverse relation-
ship between exercise and the risk of cancer progression 
regardless of other known prognostic factors [115–117]. 
A Chinese study in patients who underwent esophagec-
tomy for esophageal cancer supported the benefit of PA 
(> 9 MET-hours/week) on recurrence risk and all-cause 
mortality [120]. Data from a prospective observational 
study in kidney cancer survivors investigating PA and 
diet changes suggested a decrease in the recurrence rate 
in patients who did any PA compared with those that were 
totally inactive [118]. The only study in lung cancer survi-
vors showed better overall survival in patients who met > 9 
MET-hours/week, but no difference in the recurrence rate 
was observed [119].
In conclusion, the real impact of PA on the risk of 
relapse and cancer mortality is not well-defined. PA may 
contribute to reduced cancer-related mortality and all-
cause mortality in cancer survivors by modifying fat accu-
mulation and improving cardiovascular and skeletal mus-
cle function [129]. Numerous prospective observational 
studies consistently showed the benefit of PA on cancer 
outcomes; however, most of these studies were based on 
measures from self-reported questionnaires, including 
heterogeneous populations, and only a few performed a 
multivariable analysis to exclude the contribution of other 
confounding factors. Interventional studies with reliable 
and objective measures of PA in homogeneous popula-
tions are needed to confirm the data from observational 
studies and to evaluate the real effect of exercise on cancer 
prognosis.
Table 1  Meta-analysis of observational and interventional studies on the impact of exercise on breast cancer outcome
BC, breast cancer; HRQoL, health-related quality of life; PA, physical activity
References Population PA Outcome Results
Lahart et al. [97] 123,574 BC survivors
1994–2014
Most studies observational
Pre-diagnosis All-cause mortality HR 0.82 (95% CI 0.75–0.96)
BC mortality HR 0.73 (95% CI 0.54–0.98)
BC events HR 0.72 (95% CI 0.56–0.91)
After diagnosis All-cause mortality HR 0.52 (95% CI 0.43–0.64)
BC mortality HR 0.59 (95% CI 0.45–0.78)
BC events HR 0.79 (95% CI 0.63–0.98)
Lahart et al. [98] 5761 BC survivors from
63 randomized trials
PA intervention
After diagnosis All-cause mortality No data
BC recurrence No data
HRQoL, emotional function, perceived physi-
cal function, anxiety, and cardiorespiratory 
fitness
Small to moderate improvement
Clinical and Translational Oncology 
1 3
Exercise‑oncology: a pragmatic point 
of view for clinicians
Exercise-oncology is a new field of cancer care with the 
goal of the appropriate and rationale introduction of exercise 
programs into the overall management of cancer patients to 
take advantage of the numerous benefits associated with PA. 
Several major comprehensive cancer centers have created 
exercise-oncology units to implement these programs in a 
timely and organized manner. A collaborative work among 
rehab specialists, physiotherapists and exercise physiolo-
gists, as well as oncologists and radio-oncology specialists, 
is developed in these units.
Exercise has demonstrated numerous benefits on the 
QoL of patients with cancer throughout the history of the 
disease, ameliorating the negative impact of cancer on 
physical and psychological health and having a positive 
impact on patient survival [130–133].
Despite these benefits, many questions about PA/
exercise in cancer patients remain, as it is particularly 
challenging to elucidate how much exercise is needed to 
achieve patient improvements and how the exercise should 
be recommended and monitored by clinicians.
Table 2  Summary of prospective observational studies on physical activity and prognosis in breast cancer patients
BC, breast cancer; LTPA, leisure-time physical activity; MET-h/week, metabolic equivalent task hours per week; TNBC: triple-negative breast 
cancer
BC events: BC progression, new primary BC, recurrence of BC
Study/references Population LTPA Outcome Results
Holmes et al. [99]
Nurses’ Health Study




BC-specific mortality HR 0.50 (95% CI 0.34–0.74)
Irwin et al. [100]
HEAL Study




Overall survival HR 0.69 (95% CI 0.45–1.06)
After diagnosis
≥ 9 MET-h/week
Overall survival HR 0.33 (95% CI 0.15–0.73)
Bao et al. [101]
Shanghai BCSS
518 Women with TNBC After diagnosis
≥ 7.6 MET-h/week or ≥ 2.5 
MET-h/week
BC-specific mortality HR 0.58 (95% CI 0.39–0.86)
BC recurrence HR 0.67 (95% CI 0.46–0.96)
Schmidt et al. [102]
Germany




All-cause mortality HR 0.66 (95% CI 0.47–0.92)
BC mortality HR 0.80 (95% CI 0.53–1.21)
Cancer recurrence HR 0.65 (95% CI 0.44–0.97)
Holick et al. [103]
Florida-Boston
4482 Invasive BC 1998–2001 After diagnosis
≥ 21 MET-h/week
BC mortality HR 0.51 (95% CI 0.29–0.89)
All-cause mortality HR 0.44 (95% CI 0.32–0.60)
Ammitzboll et al. [104]
Danish Diet, Cancer and 
Health Cohort
959 BC survivors After diagnosis
≥ 8 MET-h/week
All-cause mortality HR 0.67 (95% CI 0.47–0.99)
Friedenreich et al. [105]
Canadian




BC mortality HR 0.56 (95% CI 0.38–0.82)





PA 6 months prior to diag-
nosis
BC mortality No association confirmed
BC recurrence No association confirmed
All-cause mortality HR 0.66 (95% CI 0.42–1.03)
Irwin et al. [107]
Women’s Health Initiative
4643 BC (in situ + invasive) Prior to diagnosis
≥ 9 MET-h/week
All-cause mortality HR 0.61 (95% CI 0.44–0.87)
After diagnosis
≥ 9 MET-h/week
BC mortality HR 0.61 (95% CI 0.43–0.99)
All-cause mortality HR 0.54 (95% CI 0.38–0.79)
Bertram et al. [108]
WHEL Study
2361 Women with stage I-III 
BC
Baseline active All-cause mortality HR 0.47 (95% CI 0.26–0.84)
BC events No effect
Adherence to activity 
guidelines after 1 year post-
diagnosis
All-cause mortality HR 0.65 (95% CI 0.47–0.91)
BC events No effect
Bradshaw et al. [109]
Long Island BC Study




All-cause mortality HR 0.33 (95% CI 0.22–0.48)
BC mortality HR 0.27 (95% CI 0.15–0.46)
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General PA/exercise recommendations for cancer 
patients
In 2010, the first exercise guidelines were published by 
a roundtable of the American College of Sports Medi-
cine (ACSM) based on general WHO PA guidelines to the 
general population. These guidelines consist of a minimum 
exercise recommendation: 150 min of moderate-intensity 
exercise in 3–5 days combining 2 days of resistance exer-
cise and 3 days of aerobic exercise or 70 min of high-
intensity exercise combining 1 day of resistance exercise 
and 2 days of aerobic exercise [133].
Table 3  Summary of observational studies on physical activity and prognosis in colorectal cancer patients
CRC, colorectal cancer; LTPA, leisure-time physical activity; MET-h/week, metabolic equivalent task hours per week
Study Population LTPA Outcome Results




HR 0.75 (95% CI 0.61–0.91)
HR 0.81 (95% CI 0.64–1.02)
Arem et al. [111]









HR 0.80 (95% CI 0.68–0.95)
HR 0.69 (95% CI 0.49–0.98)
Meyerhardt et al. [112]
CALGB 89803
832 Patients with stage III CRC Post-diagnosis LTPA
> 18 MET-h/week
Disease-free survival HR 0.51 (95% CI 0.26–0.97)
van Blarigan et al. [113]
CALGB 89803




Overall survival HR 0.64 (95% CI 0.45–0.92)
Meyerhardt et al. [112]
Nurses’ Health Study




HR 0.39 (95% CI 0.18–0.82)
HR 0.43 (95% CI 0.25–0.74)






RR 0.72 (95% CI 0.58–0.89)
RR 0.58 (95% CI 0.47–0.71)
Table 4  Summary of observational studies on physical activity and prognosis in prostate cancer patients
LTPA, leisure-time physical activity; MET-h/week, metabolic equivalent task hours per week; PC, prostate cancer
Study Population LTPA Outcome Results




Rate of progression HR 0.43 (95% CI 0.21–0.91)
Friedenreich et al. [116] N = 830
Stage II–IV PC
1997–2000
Post-diagnosis total activity > 119 MET-
hours/week
All-cause mortality HR 0.58 (95% CI 0.42–0.79)
Pre- and post-diagnosis activity PC mortality HR 0.56 (95% CI 0.35–0.90)







Post-diagnosis walking ≥ 90 min per week All-cause mortality HR 0.54 (95% CI 0.41–0.71)
Post-diagnosis walking ≥ 3 h per week or 
vigorous activity
All-cause mortality HR 0.51 (95% CI 0.36–0.72)
Table 5  Prospective observational studies on physical activity and prognosis in other cancers
HR, hazard ratio; LTPA, leisure-time physical activity; MET, metabolic equivalent; PA, physical activity
Study Population LTPA Outcome Results
Liss et al. [118]
Texas and San Diego
222,163 Kidney cancer survivors 
1998–2004
Any PA Kidney cancer-spe-
cific mortality
HR 0.50 (95% CI 0.27–0.93)
Sloan et al. [119]
Rochester, US
1466 Lung cancer survivors 1997–2009 Physically active Recurrence rate
Overall survival
81% versus 82% (P = 0.62)
8.4 year versus 4.4 year (P < 0.0001)
Wang et al. [120]
Chinese




HR 0.67 (95% CI 0.48–0.92)
HR 0.31 (95% CI 0.22–0.43)
Clinical and Translational Oncology 
1 3
Exercise in the cancer treatment continuum
First, it is important to highlight that exercise is feasible, 
effective and safe in patients with cancer throughout the 
course of the disease. However, there are specific recom-
mendations for the different moments of the disease and its 
therapies.
Presurgical exercise
It has been shown that presurgical high-intensity interval 
training in cancer patients is feasible and effective in improv-
ing cardiorespiratory fitness, which is typically measured as 
peak oxygen uptake  (VO2peak); this training makes sense when 
patients need to achieve a specific  VO2peak to undergo surgery, 
as noted for patients with lung cancer [134]. The intervention 
was based on high-intensity aerobic exercise (cycling) from 
50 to 100% of  VO2peak for 30 min, 5 days per week.
In another study in patients with BC, a presurgical inter-
vention consisting of 180 min of moderate aerobic exercise 
and 40 min of strength training per week was associated with 
physiological changes and alterations in gene expression in 
tumor tissue (notably, downregulation of pathways related 
to cell cycle, RNA transport and DNA replication) [135].
Exercise during chemotherapy
Several studies using PA concomitantly with neoadjuvant 
and adjuvant chemotherapy have been performed with dif-
ferent approaches, demonstrating safety, effectiveness and 
fitness improvements [136].
Exercise programs concomitant with neoadjuvant chemo-
therapy are usually focused on improving the  VO2peak level 
or maintaining it at the baseline range after cancer treatment. 
Interventions are based on at least 3 days per week with dif-
ferent durations (from 4 to 12 weeks) in 30- to 60-min ses-
sion with variable intensities, which range from 55 to 60% of 
 VO2peak at the start to 70–100% of  VO2peak at the end [137].
Exercise interventions concomitant with adjuvant therapy 
must take into account a safe starting time to be sure that 
surgical wounds are completely scarred. Different reviews 
have shown that exercise improves fitness capacity [138] 
and might reduce some cancer-related side effects, such as 
fatigue [136]. However, interventions in these studies were 
heterogeneous and did not often describe the intensity or 
type of exercise used. A recent meta-analysis suggested that 
a workload of 600 MET (intensity-minutes) was associated 
with a clinically significant improvement in fitness capac-
ity, suggesting that a 10-week program of 90 min/week of 
supervised training at 70% of  VO2peak may be sufficient 
[139–141]. Another meta-analysis found that cancer survi-
vors who completed 15 MET-h/week presented a 27% lower 
risk of cancer mortality with respect to controls, and this 
effect was greater in patients who were sedentary at pre-
diagnosis (35% lower risk) [142].
Despite the aggressiveness of cancer therapies, medium 
to high-intensity exercise and different types of exercise 
interventions are well-tolerated by most patients. Both previ-
ous reviews mentioned above focused on exercise interven-
tion during neoadjuvant and adjuvant treatments, including 
high-intensity intervention [137, 143].
In addition, resistance training has been shown to be safe 
and effective in preventing lean body mass loss and reducing 
body fat mass during neoadjuvant and adjuvant treatments 
[144].
Exercise in cancer survivors
It is well-known that cancer survivors obtain an improve-
ment in QoL, body composition and physical fitness with 
exercise [130, 131, 144–146]. Again, the challenge in this 
population is to determine how much exercise is needed to 
achieve the maximum benefits. Related to exercise inten-
sity, Gil-Rey et al. [147] showed that cancer survivors have 
an important reduction in their fitness capacity after cancer 
therapy and therefore suggest a reduction in exercise inten-
sity at the beginning of training (i.e., 41–64% of  VO2max). 
However, high-intensity training is feasible, safe and effec-
tive for cancer patients, and a shorter time of training is 
likely sufficient to obtain benefits, which should be taken 
into account in the implementation of exercise strategies 
[148].
More research is needed to determine the dose–response 
relationship between exercise and physical improvements 
given that some data from past clinical studies have sug-
gested that an exercise intensity higher than that included 
in the general WHO recommendations might be needed to 
improve patients’ health status [147].
Exercise in patients with advanced and metastatic disease
Previous studies and reviews have shown that exercise is 
a safe and effective tool to improve fitness and functional 
capacity, strength, QoL and fatigue. Fitness and functional 
capacity were assessed by the  VO2peak and 6-min walking 
tests, showing significantly better results compared with the 
control group. In these studies, the aerobic exercise intensity 
ranged from 55 to 75% of  VO2peak [15, 16, 19, 29]. Mus-
cle strength was assessed with the one-repetition maximum 
(1RM) or estimated 1RM test (lower and upper limbs), and 
exercise intensity in these studies ranged from 40 to 80% of 
1RM. Program durations ranged from 5 to 12 weeks [22, 
25]. With respect to body composition, significant changes 
were observed in lean mass, but no changes in fat mass, 
body mass or BMI were observed in previous studies. The 
low intensity of the exercise intervention (from 55 to 70% 
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of  VO2peak) might be a reason for these inconsistent results 
[15, 16, 33].
Exercise supervision
Although the benefits of exercise are well-established, the 
exercise dose–response and the best type of exercise in terms 
of duration and intensity remain unclear, making it difficult 
to establish how to provide specific recommendations to 
each individual patient and how to supervise the patient’s 
exercise by clinicians. With these caveats in mind, it might 
be wise to differentiate between patients who clearly need 
specialist counseling (as those under active treatment or 
metastatic patients, and all patients with side effects who 
limit them physically) and patients who do not (survival with 
limited side effects) (Fig. 1). An exercise-oncology special-
ist is an exercise professional with a previous background 
that includes a general qualification in exercise and health 
with specific knowledge in oncology items. Related to the 
oncology items, general knowledge about cancer biology, 
biomarkers and treatments and their side effects should be 
used to adapt to and individualize exercise to patients’ needs.
Challenges for patients: general supervision
For those patients who do not present the need for specialist 
counseling, the control of patients by informed clinicians 
could be sufficient to achieve reasonable results. In this 
respect, there are some specific guidelines that could be fol-
lowed by patients and supervised by a nonspecialist with 
the help of different tests, devices or scales. For example, 
following WHO/ACSM guidelines or achieving more than 
10,000 steps per day [150] are reasonable goals for cancer 
survivors (Table 6).
Fig. 1  Distinguishing between patients who need specialist coun-
seling and those who do not. Adaptation to the triage model for pop-
ulation-based screening of cancer survivors for weight management 
and physical activity interventions. Modified from National Acad-
emies of Sciences, Engineering, and Medicine 2018 [149]. Set. = set-
ting; Tr. = training of professional; LS. = level of supervision. Spe-
cialist refers to clinicians, physical therapists, occupational therapists, 
dieticians, and clinical exercise physiologists
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New technologies are improving methods to supervise 
the quality and quantity of exercise [153]. While behavioral 
interventions using text messages (with or without educa-
tional material and internet support) have produced limited 
effects on exercise adherence, mobile applications have been 
shown to be an effective and useful tool for both patients and 
providers to establish a healthy lifestyle. To achieve signifi-
cant changes, it has been observed that these apps should 
include self-monitoring merged with other motivational 
techniques (goal setting, feedback on performance, review 
of goals, prompts, planning or barrier identifications, among 
others), allowing better supervision and control for patients 
and trainers [153].
Challenges for clinicians: learning exercise techniques
At present, exercise provides empowerment among health 
care providers, presenting a new challenge for them. One of 
the most important issues to address is who might prescribe 
and control exercise. It is possible that multidisciplinary 
committees, including oncologists, rehab departments and 
exercise physiologists, should be created to provide patients 
with the best counseling and training physicians to help indi-
viduals not requiring special help (Fig. 2). 
However, while this scenario seems far away, other 
achievable proposals are feasible. The education of clini-
cians taking care of cancer patients and survivors about 
exercise techniques and control is a crucial point. Education 
and training should ideally start during university studies, 
although few institutions worldwide provide exercise theory 
and training to their future professionals. This education 
would have an impact not only in cancer patients but also 
on many other common pathologies such as cardiovascular, 
metabolic, joint and other diseases [154]. In accordance, 
patients’ associations playing a crucial role at present in pro-
viding exercise training and assistance until exercise will be 
included in the usual care.
Future lines of research
Despite the increasing number of studies addressing the ben-
efits of exercise for cancer patients and survivors in the last 
5 years, further research remains essential to clarify many 
unanswered questions. The establishment of new, more 
concrete guidelines for exercise in cancer patients is neces-
sary not only for the exercise-oncology specialist but also 
for oncologists and other clinicians who take care of cancer 
patients.
There is an urgent need to further clarify the biologi-
cal mechanism that makes exercise an effective method of 
intervention to decrease cancer incidence and mortality 
and to improve overall health in cancer patients. Studies of 
the modification of biological biomarkers before and after 
exercise are crucial for understanding the underlying mech-
anisms through which exercise can exert its influence on 
cancer biology. Several preclinical studies (discussed above) 
and clinical studies of small sample sizes have provided pre-
liminary evidence on the relevance of the immune system, 
cytokines and insulin-related pathways [155]; however, 
because the evidence is preliminary, larger and statistically 
powerful studies are required.
In addition, new studies aimed at identifying the optimal 
intensity and duration of PA are needed. The characteristics 
of cancer survivors differ from those of the healthy popula-
tion to whom the recommendations of the different health 
organizations are directed.
Table 6  General challenges for patients without specialist counseling needs based on existing guidelines
MET, metabolic equivalent
Recommendation Challenge Intensity
WHO/ACSM guidelines 150 min per week
 30 min/3 times “aerobic” exercise
 30 min/2 times strength exercises
Moderate
75 min per week
 25 min/2 times aerobic exercise
 25 min/1 time strength exercises
High intensity
Survival recommendations [99, 107, 147, 151] 9 MET corresponding to 180 min of walking 5 km/h
Review psychological benefits [152] 12 MET; 90–120 min Moderate intensity
Minimum step recommendations [150] < 5000 steps/day “Sedentary lifestyle index”
5000–7499 steps/day It is typical of daily activity excluding sports/
exercise and might be considered “low 
active”
7500–9999 “Somewhat active”
≥ 10,000 steps/day “Active”
Individuals who take > 12,500 steps/day “Highly active”
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The best method of introducing exercise into the lifestyle 
of patients is also a matter to be addressed. The most effec-
tive behavioral interventions to achieve long-term changes 
in a patient’s lifestyle must be defined, bearing in mind that 
cancer diagnosis and treatment are “learning moments” in 
which patients are willing to change their daily activities to 
improve their health. The feasibility of using new technolo-
gies, such as mobile health applications and wrist and watch 
bands, as well as interventions based on social networks 
should be investigated to favor adherence and motivation to 
these programs of adapted PA.
In addition, future research on intervention in metastatic 
cancer stages should be performed due to the lack of knowl-
edge in this area and the potential interest in improving the 
tolerance and effectiveness of treatments and the QoL of 
patients, many of whom can live today for many years after 
relapse due to the effective and sustained disease palliation 
that can be achieved with modern systemic treatments.
Conclusions
Regular PA is associated with major benefits to human 
health, including a reduced risk of some cancers.
The mechanisms through which exercise exerts its antitu-
mor activity are still poorly understood but might be related 
to a direct effect on tumor cells (inhibition of tumor cell pro-
liferation, induction of apoptosis, upregulation of tumor sup-
pressor genes, anti-inflammatory effects) or to an enhance-
ment of immune function.
There is convincing evidence that regular PA reduces the 
risk of colorectal cancer, while the reduction in postmeno-
pausal BC and endometrial cancer risk is judged as probable. 
The effect of PA on the risk of other tumors is less evident 
but still possible.
Several epidemiological studies have suggested an asso-
ciation of regular PA with reduced cancer-related and all-
cause mortality in some tumor types, particularly BC and 
colorectal cancer. The minimum amount of PA needed to 
achieve such a benefit is still unknown, although the US 
recommendations suggest that a minimum 10 MET-hours/
week (equivalent to ≥ 150 min of moderate-intensity PA) is 
needed.
Exercise-oncology is a field of cancer care in which 
the goal is the introduction of exercise programs into the 
overall management of cancer patients. The first exercise 
guidelines for cancer patients were published in 2010 by 
the ACSM. These guidelines, which are mainly based on 
general WHO guidelines to the general population, con-
sider that regular PA in cancer patients is safe and exerts 
positive effects in patients at multiple levels, particularly 
QoL. Exercise programs in cancer patients are feasible 
along the course of the disease, including the presurgi-
cal period, during adjuvant antitumor medical treatment 
(including chemotherapy) and in cancer survivors; a sum-
mary of these recommendations is shown in Table 7. How-
ever, the experience with regular exercise in metastatic 
cancer patients is limited. 
The introduction of exercise programs into the global 
management of cancer patients remains a challenge due to 
Fig. 2  Specialists and activi-
ties that should be developed 
by each specialist to achieve an 
adequate exercise intervention 
for oncologic patients while 
taking into account training 
principles adapted to exercise-
oncology
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conceptual and logistic issues. The most effective behav-
ioral interventions to achieve long-term changes in a 
patient’s lifestyle must be defined. New technologies, such 
as mobile health applications and wrist and watch bands 
(the so-called “mHealth”), can be of great help to monitor 
the compliance to these programs. The optimal intensity 
and duration of PA should be defined with more precision 
in future studies. Regarding logistics, the intervention of 
both exercise-oncology specialists and trained clinicians 
is probably necessary at different time points to provide 
the best care. Several major comprehensive cancer centers 
have created exercise-oncology units to implement these 
programs in a timely and organized manner, and these 
models could serve as a reference for other institutions.
Acknowledgements We would like to thank to Fernando Rico-Villad-
emoros, MD (COCIENTE S.L., Madrid, Spain) for his editorial assis-
tance; his participation was funded by the Spanish Society of Medical 
Oncology (SEOM).
Author’s contribution All authors were involved in the conception of 
this work, drafting and/or revising the manuscript, and approved the 
final version.
Funding This positioning statement was funded by the Spanish Society 
of Medical Oncology (SEOM).
Compliance with ethical standards 
Conflict of interest MP declares that she have no conflict of interest; 
SC declares that she have no conflict of interest; JA received institu-
tional research grants from Merck Serono and Novartis; CE received 
speaker’s honoraria from AstraZeneca, Roche, Novartis and Pfizer; 
MAS-P received consulting/advisory fees from AstraZeneca, Pfizer 
and Amgen, and speakers’ honoraria from Amgen, Roche and Pfizer; 
AL declares that he have no conflict of interest; MM has received re-
search grants from Roche and Novartis, consulting/advisory fees from 
AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, 
PharmaMar, Eli Lilly, PUMA Taiho Oncology and Pfizer, and speak-
ers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis 
and Pfizer.
Ethical approval The manuscript does not contain any studies with 
human participants or animals performed by any of the authors.
Informed consent Informed consent/ethical approval is not required 
for this type of project.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. World Health Organization. Physical activity. Geneva: WHO; 
2018.
 2. National Cancer Institute. Cancer survivors and physical activity. 
2018. https ://progr essre port.cance r.gov/after /physi cal_activ ity. 
Accessed 5 June 2019.
 3. Figueira A, Cortinhas A, Soares J, Leitão J, Ferreira R, Duarte 
J. Efficacy of exercise on breast cancer outcomes: a systematic 
review and meta-analysis of preclinical data. Int J Sports Med. 
2018;39:327–42.
 4. Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, 
Devi GR, Palmer G, Jones LW, Dewhirst MW. Modulation of 
murine breast tumor vascularity, hypoxia, and chemotherapeutic 
response by exercise. J Natl Cancer Inst. 2015;107:djv040.
 5. Jones LW, Eves N, Courneya K, Chiu B, Baracos V, Hanson J, 
Johnson L, Mackey J. Effects of exercise training on antitumor 
efficacy of doxorubicin in MDA-MB-231 breast cancer xeno-
grafts. Clin Cancer Res. 2005;11:6695–8.
 6. Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry 
WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, 
Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turk-
ington TG, Dewhirst MW. Modulation of circulating angiogenic 
factors and tumor biology by aerobic training in breast cancer 
patients receiving neoadjuvant chemotherapy. Cancer Prev Res. 
2013;6:925–37.
 7. Sturgeon K, Schadler K, Muthukumaran G, Ding D, Bajulaiye A, 
Thomas NJ, Ferrari V, Ryeom S, Libonati JR. Concomitant low-
dose doxorubicin treatment and exercise. Am J Physiol Regul 
Integr Comp Physiol. 2014;307:R685–92.
 8. Ruiz-Casado A, Martín-Ruiz A, Pérez LM, Provencio M, Fiuza-
Luces C, Lucia A. Exercise and the hallmarks of cancer. Trends 
Cancer. 2017;3:423–41.
 9. Colbert LH, Mai V, Tooze J, Perkins S, Berrigan D, Hursting S. 
Negative energy balance induced by voluntary wheel running 
inhibits polyp development in APCMin mice. Carcinogenesis. 
2006;27:2103–7.
 10. Leung P-S, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. 
Exercise alters the IGF axis in vivo and increases p53 protein in 
prostate tumor cells in vitro. J Appl Physiol. 2004;96:450–4.
 11. Ouyang P, Jiang Y, Doan HM, Xie L, Vasquez D, Welti R, Su X, 
Lu N, Herndon B, Yang SS, Jeannotte R, Wang W. Weight loss 
via exercise with controlled dietary intake may affect phospho-
lipid profile for cancer prevention in murine skin tissues. Cancer 
Prev Res. 2010;3:466–77.
 12. Xie L, Jiang Y, Ouyang P, Chen J, Doan H, Herndon B, Syl-
vester JE, Zhang K, Molteni A, Reichle M, Zhang R, Haub MD, 
Baybutt RC, Wang W. Effects of dietary calorie restriction or 
exercise on the PI3K and ras signaling pathways in the skin of 
mice. J Biol Chem. 2007;282:28025–35.
 13. Yu M, King B, Ewert E, Su X, Mardiyati N, Zhao Z, Wang W. 
Exercise activates p53 and negatively regulates IGF-1 path-
way in epidermis within a skin cancer model. PLoS ONE. 
2016;11:e0160939.
 14. Zhu Z, Jiang W, Zacher JH, Neil ES, McGinley JN, Thompson 
HJ. Effects of energy restriction and wheel running on mammary 
carcinogenesis and host systemic factors in a rat model. Cancer 
Prev Res. 2012;5:414–22.
 15. Kalaany NY, Sabatini DM. Tumours with PI3K activation are 
resistant to dietary restriction. Nature. 2009;458:725–31.
 16. Jiang W, Zhu Z, Thompson HJ. Effects of physical activity and 
restricted energy intake on chemically induced mammary car-
cinogenesis. Cancer Prev Res. 2009;2:338–44.
 17. Zhu Z, Jiang W, Sells JL, Neil ES, McGinley JN, Thomp-
son HJ. Effect of nonmotorized wheel running on mammary 
 Clinical and Translational Oncology
1 3
carcinogenesis: circulating biomarkers, cellular processes, and 
molecular mechanisms in rats. Cancer Epidemiol Biomark Prev. 
2008;17:1920–9.
 18. Baltgalvis KA, Berger FG, Peña MMO, Davis JM, Carson JA. 
Effect of exercise on biological pathways in ApcMin/+ mouse 
intestinal polyps. J Appl Physiol. 2008;104:1137–43.
 19. Ju J, Nolan B, Cheh M, Bose M, Lin Y, Wagner GC, Yang CS. 
Voluntary exercise inhibits intestinal tumorigenesis in Apc 
Min/+ mice and azoxymethane/dextran sulfate sodium-treated 
mice. BMC Cancer. 2008;8:316.
 20. Horak M, Zlamal F, Iliev R, Kucera J, Cacek J, Svobodova L, 
Hlavonova Z, Kalina T, Slaby O, Bienertova-Vasku J. Exercise-
induced circulating microRNA changes in athletes in various 
training scenarios. PLoS ONE. 2018;13:e0191060.
 21. Khori V, Amani Shalamzari S, Isanejad A, Alizadeh Ali M, 
Alizadeh S, Khodayari S, Khodayari H, Shahbazi S, Zahedi A, 
Sohanaki H, Khaniki M, Mahdian R, Saffari M, Fayad R. Effects 
of exercise training together with tamoxifen in reducing mam-
mary tumor burden in mice: possible underlying pathway of miR-
21. Eur J Pharmacol. 2015;765:179–87.
 22. Dethlefsen C, Hansen LS, Lillelund C, Andersen C, Gehl J, 
Christensen JF, Pedersen BK, Hojman P. Exercise-induced 
catecholamines activate the hippo tumor suppressor pathway 
to reduce risks of breast cancer development. Cancer Res. 
2017;77:4894–904.
 23. Lu YP, Lou YR, Nolan B, Peng QY, Xie JG, Wagner GC, Conney 
AH. Stimulatory effect of voluntary exercise or fat removal (par-
tial lipectomy) on apoptosis in the skin of UVB light-irradiated 
mice. Proc Natl Acad Sci USA. 2006;103:16301–6.
 24. Higgins KA, Park D, Lee GY, Curran WJ, Deng X. Exercise-
induced lung cancer regression: mechanistic findings from a 
mouse model. Cancer. 2014;120:3302–10.
 25. Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y, Lu YP, 
Wagner GC, Conney AH. Inhibitory effect of voluntary running 
wheel exercise on the growth of human pancreatic Panc-1 and 
prostate PC-3 xenograft tumors in immunodeficient mice. Oncol 
Rep. 2008;19:1583–8.
 26. Zheng X, Cui X-X, Huang M-T, Liu Y, Wagner GC, Lin Y, Shih 
WJ, Lee M-J, Yang CS, Conney AH. Inhibition of progression of 
androgen-dependent prostate LNCaP tumors to androgen inde-
pendence in SCID mice by oral caffeine and voluntary exercise. 
Nutr Cancer. 2012;64:1029–37.
 27. Zhu Z, Jiang W, McGinley JN, Thompson HJ. Energetics and 
mammary carcinogenesis: effects of moderate-intensity running 
and energy intake on cellular processes and molecular mecha-
nisms in rats. J Appl Physiol. 2009;106:911–8.
 28. Soliman S, Aronson WJ, Barnard RJ. Analyzing serum-stimu-
lated prostate cancer cell lines after low-fat, high-fiber diet and 
exercise intervention. Evid Based Complement Altern Med. 
2011;2011:529053.
 29. Barnard RJ, Hong Gonzalez J, Liva ME, Ngo TH. Effects of a 
low-fat, high-fiber diet and exercise program on breast cancer 
risk factors in vivo and tumor cell growth and apoptosis in vitro. 
Nutr Cancer. 2006;55:28–34.
 30. Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Ped-
ersen BK. Exercise-induced muscle-derived cytokines inhibit 
mammary cancer cell growth. Am J Physiol Endocrinol Metabol. 
2011;301:E504–10.
 31. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, 
Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, Hill JA, Vir-
gin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine 
B. Exercise-induced BCL2-regulated autophagy is required for 
muscle glucose homeostasis. Nature. 2012;481:511–5.
 32. Piguet A-C, Saran U, Simillion C, Keller I, Terracciano L, 
Reeves HL, Dufour J-F. Regular exercise decreases liver tumors 
development in hepatocyte-specific PTEN-deficient mice inde-
pendently of steatosis. J Hepatol. 2015;62:1296–303.
 33. Sanchis-Gomar F. Sestrins: novel antioxidant and AMPK-
modulating functions regulated by exercise? J Cell Physiol. 
2013;228:1647–50.
 34. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. 
Tumour hypoxia, chemotherapeutic resistance and hypoxia-
related therapies. Cancer Treat Rev. 2003;29:297–307.
 35. Jones LW, Viglianti BL, Tashjian JA, Kothadia SM, Keir ST, 
Freedland SJ, Potter MQ, Jung Moon E, Schroeder T, Herndon 
JE, Dewhirst MW. Effect of aerobic exercise on tumor physiol-
ogy in an animal model of human breast cancer. J Appl Physiol. 
2010;108:343–8.
 36. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, 
Fels D, Dewhirst MW, Dyck JRB, Nagendran J, Flores CT, 
Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, Freed-
land SJ. Exercise modulation of the host-tumor interaction in 
an orthotopic model of murine prostate cancer. J Appl Physiol. 
2012;113:263–72.
 37. McCullough DJ, Nguyen LMD, Siemann DW, Behnke BJ. 
Effects of exercise training on tumor hypoxia and vascular func-
tion in the rodent preclinical orthotopic prostate cancer model. J 
Appl Physiol. 2013;115:1846–54.
 38. McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modu-
lation of blood flow, hypoxia, and vascular function in ortho-
topic prostate tumors during exercise. J Natl Cancer Inst. 
2014;106:dju036.
 39. Schadler KL, Thomas NJ, Galie PA, Bhang DH, Roby KC, Addai 
P, Till JE, Sturgeon K, Zaslavsky A, Chen CS, Ryeom S. Tumor 
vessel normalization after aerobic exercise enhances chemothera-
peutic efficacy. Oncotarget. 2016;7:65429–40.
 40. Zhang QB, Zhang BH, Zhang KZ, Meng XT, Jia QA, Zhang 
QB, Bu Y, Zhu XD, Ma DN, Ye BG, Zhang N, Ren ZG, Sun 
HC, Tang ZY. Moderate swimming suppressed the growth and 
metastasis of the transplanted liver cancer in mice model: with 
reference to nervous system. Oncogene. 2016;35:4122–31.
 41. Wolff G, Davidson SJ, Wrobel JK, Toborek M. Exercise 
maintains blood–brain barrier integrity during early stages of 
brain metastasis formation. Biochem Biophys Res Commun. 
2015;463:811–7.
 42. Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in 
blood-brain barrier (BBB) and brain metastases (review). Mol 
Med Rep. 2014;9:779–85.
 43. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next 
generation. Cell. 2011;144:646–74.
 44. Koelwyn GJ, Quail DF, Zhang X, White RM, Jones LW. Exer-
cise-dependent regulation of the tumour microenvironment. Nat 
Rev Cancer. 2017;17:620–32.
 45. Wiggins JM, Opoku-Acheampong AB, Baumfalk DR, Siemann 
DW, Behnke BJ. Exercise and the tumor microenvironment. 
Exerc Sport Sci Rev. 2018;46:56–64.
 46. Zielinski MR, Muenchow M, Wallig MA, Horn PL, Woods 
JA. Exercise delays allogeneic tumor growth and reduces intra-
tumoral inflammation and vascularization. J Appl Physiol. 
2004;96:2249–56.
 47. Almeida PWM, Gomes-Filho A, Ferreira AJ, Rodrigues CEM, 
Dias-Peixoto MF, Russo RC, Teixeira MM, Cassali GD, Ferreira 
E, Santos IC, Garcia AMC, Silami-Garcia E, Wisløff U, Pussieldi 
GA. Swim training suppresses tumor growth in mice. J Appl 
Physiol. 2009;107:261–5.
 48. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, 
Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz 
L, Rogers CJ, Northoff H, Abbasi A, Simon P. Position state-
ment. Part one: immune function and exercise. Exerc Immunol 
Rev. 2011;17:6–63.
Clinical and Translational Oncology 
1 3
 49. Idorn M, Hojman P. Exercise-dependent regulation of NK cells 
in cancer protection. Trends Mol Med. 2016;22:565–77.
 50. Kruijsen-Jaarsma M, Revesz D, Bierings MB, Buffart LM, 
Takken T. Effects of exercise on immune function in patients 
with cancer: a systematic review. Exerc Immunol Rev. 
2013;19:120–43.
 51. Pedersen L, Idorn M, Olofsson Gitte H, Lauenborg B, Nookaew 
I, Hansen Rasmus H, Johannesen Helle H, Becker Jürgen C, Ped-
ersen Katrine S, Dethlefsen C, Nielsen J, Gehl J, Pedersen Bente 
K, Thor Straten P, Hojman P. Voluntary running suppresses 
tumor growth through epinephrine- and IL-6-dependent NK cell 
mobilization and redistribution. Cell Metabol. 2016;23:554–62.
 52. Lu Q, Ceddia MA, Price EA, Ye SM, Woods JA. Chronic 
exercise increases macrophage-mediated tumor cytolysis in 
young and old mice. Am J Physiol Regul Integr Comp Physiol. 
1999;276:R482–9.
 53. Abdalla DR, Murta EFC, Michelin MA. The influence of 
physical activity on the profile of immune response cells and 
cytokine synthesis in mice with experimental breast tumors 
induced by 7,12-dimethylbenzanthracene. Eur J Cancer Prev. 
2013;22:251–8.
 54. Abdalla DR, Aleixo AAR, Murta EFC, Michelin MA. Innate 
immune response adaptation in mice subjected to administration 
of DMBA and physical activity. Oncol Lett. 2014;7:886–90.
 55. Kizaki T, Takemasa T, Sakurai T, Izawa T, Hanawa T, Kamiya 
S, Haga S, Imaizumi K, Ohno H. Adaptation of macrophages to 
exercise training improves innate immunity. Biochem Biophys 
Res Commun. 2008;372:152–6.
 56. Koelwyn GJ, Wennerberg E, Demaria S, Jones LW. Exercise 
in regulation of inflammation-immune axis function in can-
cer initiation and progression. Oncology (Williston Park). 
2015;29(908–20):22.
 57. Murphy EA, Davis JM, Brown AS, Carmichael MD, Mayer EP, 
Ghaffar A. Effects of moderate exercise and oat β-glucan on lung 
tumor metastases and macrophage antitumor cytotoxicity. J Appl 
Physiol. 2004;97:955–9.
 58. Goh J, Tsai J, Bammler TK, Farin FM, Endicott E, Ladiges WC. 
Exercise training in transgenic mice is associated with attenua-
tion of early breast cancer growth in a dose-dependent manner. 
PLoS ONE. 2013;8:e80123.
 59. McClellan JL, Steiner JL, Day SD, Enos RT, Davis MJ, Singh 
UP, Murphy EA. Exercise effects on polyp burden and immune 
markers in the ApcMin/+ mouse model of intestinal tumorigen-
esis. Int J Oncol. 2014;45:861–8.
 60. Wang J, Song H, Tang X, Yang Y, Vieira VJ, Niu Y, Ma Y. Effect 
of exercise training intensity on murine T-regulatory cells and 
vaccination response. Scand J Med Sci Sports. 2012;22:643–52.
 61. Hampras SS, Nesline M, Wallace PK, Odunsi K, Furlani N, 
Davis W, Moysich KB. Predictors of immunosuppressive regu-
latory T lymphocytes in healthy women. J Cancer Epidemiol. 
2012;2012:191090.
 62. Davis JM, Kohut ML, Jackson DA, Colbert LH, Mayer EP, Ghaf-
far A. Exercise effects on lung tumor metastases and in vitro 
alveolar macrophage antitumor cytotoxicity. Am J Physiol Regul 
Integr Comp Physiol. 1998;274:R1454–9.
 63. Frellstedt L, Waldschmidt I, Gosset P, Desmet C, Pirottin D, 
Bureau F, Farnir F, Franck T, Dupuis-Tricaud M-C, Lekeux 
P, Art T. Training modifies innate immune responses in blood 
monocytes and in pulmonary alveolar macrophages. Am J Respir 
Cell Mol Biol. 2014;51:135–42.
 64. Fiuza-Luces C, Garatachea N, Berger NA, Lucia A. Exercise is 
the real polypill. Physiology. 2013;28:330–58.
 65. Aoi W, Naito Y, Takagi T, Tanimura Y, Takanami Y, Kawai Y, 
Sakuma K, Hang LP, Mizushima K, Hirai Y, Koyama R, Wada 
S, Higashi A, Kokura S, Ichikawa H, Yoshikawa T. A novel 
myokine, secreted protein acidic and rich in cysteine (SPARC), 
suppresses colon tumorigenesis via regular exercise. Gut. 
2012;62:882–9.
 66. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory 
therapy for rheumatic diseases—myokine regulation. Nat Rev 
Rheumatol. 2015;11:86–97.
 67. World Health Organization. Assessing national capacity for the 
prevention and control of noncommunicable diseases. Geneva: 
WHO; 2012.
 68. Leitzmann M, Powers H, Anderson AS, Scoccianti C, Ber-
rino F, Boutron-Ruault M-C, Cecchini M, Espina C, Key TJ, 
Norat T, Wiseman M, Romieu I. European code against can-
cer 4th edition: physical activity and cancer. Cancer Epidemiol. 
2015;39:S46–55.
 69. World Cancer Research Fund/American Institute for Cancer 
Research. Food, nutrition, physical activity, and the prevention 
of cancer: a global perspective. Washington, DC: AICR; 2007.
 70. World Cancer Research Fund/American Institute for Cancer 
Research. Food, nutrition, physical activity, and colorectal can-
cer. 2017. http://wcrf.org/color ectal -cance r-2017. Accessed 5 
June 2019.
 71. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, 
Kitahara CM, Keadle SK, Arem H, Berrington de Gonzalez A, 
Hartge P, Adami H-O, Blair CK, Borch KB, Boyd E, Check 
DP, Fournier A, Freedman ND, Gunter M, Johannson M, Khaw 
K-T, Linet MS, Orsini N, Park Y, Riboli E, Robien K, Schairer 
C, Sesso H, Spriggs M, Van Dusen R, Wolk A, Matthews CE, 
Patel AV. Association of leisure-time physical activity with risk 
of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 
2016;176:816–25.
 72. Keum N, Bao Y, Smith-Warner SA, Orav J, Wu K, Fuchs CS, 
Giovannucci EL. Association of physical activity by type and 
intensity with digestive system cancer risk. JAMA Oncol. 
2016;2:1146–53.
 73. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, 
Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, 
Cercy K, Vos T, Murray CJL, Forouzanfar MH. Physical activity 
and risk of breast cancer, colon cancer, diabetes, ischemic heart 
disease, and ischemic stroke events: systematic review and dose-
response meta-analysis for the Global Burden of Disease Study 
2013. BMJ. 2016;354:i3857.
 74. World Cancer Research Fund/American Institute for Cancer 
Research. Food, nutrition, physical activity, and the prevention 
of breast cancer. 2010. http://www.aicr.org/conti nuous -updat 
e-proje ct/repor ts/Breas t-Cance r-2010-Repor t.pdf. Accessed 10 
April 2017.
 75. Catsburg C, Kirsh VA, Soskolne CL, Kreiger N, Bruce E, Ho T, 
Leatherdale ST, Rohan TE. Associations between anthropomet-
ric characteristics, physical activity, and breast cancer risk in a 
Canadian cohort. Breast Cancer Res Treat. 2014;145:545–52.
 76. Lope V, Martín M, Castelló A, Casla S, Ruiz A, Baena-Cañada 
JM, Casas AM, Calvo L, Bermejo B, Muñoz M, Ramos M, de 
Juan-Ferré A, Jara C, Antón A, Jimeno MÁ, Lluch A, Antolín 
S, García-Sáenz JÁ, Estévez P, Arriola-Arellano E, Gavilá J, 
Pérez-Gómez B, Carrasco E, Pollán M. Physical activity and 
breast cancer risk by pathological subtype. Gynecol Oncol. 
2017;144:577–85.
 77. World Cancer Research Fund/American Institute for Cancer 
Research. Food, nutrition, physical activity, and the prevention 
of endometrial cancer. 2013. http://www.wcrf.org/sites /defau lt/
files /Endom etria l-Cance r-2013-Repor t. Accessed 5 June 2019.
 78. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitz-
mann M. A systematic review and meta-analysis of physi-
cal activity and endometrial cancer risk. Eur J Epidemiol. 
2015;30:397–412.
 Clinical and Translational Oncology
1 3
 79. Brenner DR, Yannitsos DH, Farris MS, Johansson M, Frieden-
reich CM. Leisure-time physical activity and lung cancer 
risk: a systematic review and meta-analysis. Lung Cancer. 
2016;95:17–27.
 80. World Cancer Research Fund International/American Institute 
for Cancer Research. Continuous update project report: diet, 
nutrition, physical activity and liver cancer. 2015. http://www.
wcrf.org/sites /defau lt/files /Liver -Cance r-2015-Repor t.pdf. 
Accessed 5 June 2019.
 81. World Cancer Research Fund/American Institute for Cancer 
Research. Diet, nutrition, physical activity and oesophageal 
cancer. 2016. http://www.wcrf.org/sites /defau lt/files /Oesop 
hagea l-Cance r-2016-Repor t.pdf. Accessed 5 June 2019.
 82. Behrens G, Jochem C, Keimling M, Ricci C, Schmid D, Leitz-
mann MF. The association between physical activity and gas-
troesophageal cancer: systematic review and meta-analysis. 
Eur J Epidemiol. 2014;29:151–70.
 83. World Cancer Research Fund/American Institute for Cancer 
Research. Diet, nutrition, physical activity and stomach cancer. 
2016. http://www.wcrf.org/sites /defau lt/files /Stoma ch-Cance 
r-2016-Repor t.pdf. Accessed 5 June 2019.
 84. World Cancer Research Fund/American Institute for Cancer 
Research. Diet, nutrition, physical activity, and prostate cancer. 
2014. http://www.wcrf.org/sites /defau lt/files /Prost ate-Cance 
r-2014-Repor t.pdf. Accessed 5 June 2019.
 85. Shephard RJ. Physical activity and prostate cancer: an updated 
review. Sports Med. 2017;47:1055–73.
 86. World Cancer Research Fund/American Institute for Cancer 
Research. Food, nutrition, physical activity, and the prevention 
of ovarian cancer. 2014. http://www.dieta ncanc errep ort.org/
cup/cupre sourc es.php. Accessed 5 June 2019.
 87. Cannioto RA, Moysich KB. Epithelial ovarian cancer and rec-
reational physical activity: a review of the epidemiological 
literature and implications for exercise prescription. Gynecol 
Oncol. 2015;137:559–73.
 88. Huang T, Eliassen AH, Hankinson SE, Okereke OI, Kubzan-
sky LD, Wang M, Poole EM, Chavarro JE, Tworoger SS. A 
prospective study of leisure-time physical activity and risk of 
incident epithelial ovarian cancer: impact by menopausal sta-
tus. Int J Cancer. 2016;138:843–52.
 89. World Cancer Research Fund/American Institute for Cancer 
Research. Continous Update Project Expert Report 2018. Food, 
nutrition, physical activity, and the prevention of pancreatic 
cancer. Available at http://dieta ndcan cerre port.org. Accesed 4 
June 2019.
 90. Farris MS, Mosli MH, McFadden AA, Friedenreich CM, 
Brenner DR. The association between leisure time physical 
activity and pancreatic cancer risk in adults: a systematic 
review and meta-analysis. Cancer Epidemiol Biomark Prev. 
2015;24:1462–73.
 91. Noor NM, Banim PJR, Luben RN, Khaw K-T, Hart AR. Inves-
tigating physical activity in the etiology of pancreatic cancer. 
Pancreas. 2016;45:388–93.
 92. World Cancer Research Fund/American Institute for Cancer 
Research. Diet, nutrition, physical activity and kidney cancer. 
2015. www.wcrf/kidne y-cance r-2015. Accessed 5 June 2019.
 93. Behrens G, Leitzmann MF. The association between physical 
activity and renal cancer: systematic review and meta-analysis. 
Br J Cancer. 2013;108:798–811.
 94. World Cancer Research Fund/American Institute for Cancer 
Research. Diet, nutrition, physical activity and bladder cancer. 
2015. http://www.wcrf.org/sites /defau lt/files /Bladd er-Cance 
r-2015-Repor t.pdf. Accessed 5 June 2019.
 95. Keimling M, Behrens G, Schmid D, Jochem C, Leitz-
mann MF. The association between physical activity and 
bladder cancer: systematic review and meta-analysis. Br J Can-
cer. 2014;110:1862–70.
 96. Jochem C, Leitzmann MF, Keimling M, Schmid D, Behrens G. 
Physical activity in relation to risk of hematologic cancers: a 
systematic review and meta-analysis. Cancer Epidemiol Biomark 
Prev. 2014;23:833–46.
 97. Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical 
activity, risk of death and recurrence in breast cancer survivors: a 
systematic review and meta-analysis of epidemiological studies. 
Acta Oncol. 2015;54:635–54.
 98. Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical 
activity for women with breast cancer after adjuvant therapy. 
Cochrane Database Syst Rev. 2018;1:CD011292.
 99. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz 
GA. Physical activity and survival after breast cancer diagnosis. 
JAMA. 2005;293:2479–86.
 100. Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin 
K, Gilliland FD, Baumgartner RN, Baumgartner KB, Bernstein 
L. Influence of pre- and postdiagnosis physical activity on mor-
tality in breast cancer survivors: the health, eating, activity, and 
lifestyle study. J Clin Oncol. 2008;26:3958–64.
 101. Bao P-P, Zhao G-M, Shu X-O, Peng P, Cai H, Lu W, Zheng 
Y. Modifiable lifestyle factors and triple-negative breast cancer 
survival. Epidemiology. 2015;26:909–16.
 102. Schmidt ME, Chang-Claude J, Vrieling A, Seibold P, Heinz J, 
Obi N, Flesch-Janys D, Steindorf K. Association of pre-diagnosis 
physical activity with recurrence and mortality among women 
with breast cancer. Int J Cancer. 2013;133:1431–40.
 103. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff 
L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. 
Physical activity and survival after diagnosis of invasive breast 
cancer. Cancer Epidemiol Biomark Prev. 2008;17:379–86.
 104. Ammitzbøll G, Søgaard K, Karlsen RV, Tjønneland A, Johansen 
C, Frederiksen K, Bidstrup P. Physical activity and survival in 
breast cancer. Eur J Cancer. 2016;66:67–74.
 105. Friedenreich CM, Gregory J, Kopciuk KA, Mackey JR, Courneya 
KS. Prospective cohort study of lifetime physical activity and 
breast cancer survival. Int J Cancer. 2009;124:1954–62.
 106. Sternfeld B, Weltzien E, Quesenberry CP, Castillo AL, Kwan M, 
Slattery ML, Caan BJ. Physical activity and risk of recurrence 
and mortality in breast cancer survivors: findings from the LACE 
study. Cancer Epidemiol Biomark Prev. 2009;18:87–95.
 107. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, 
Stefanick ML, Wactawski-Wende J, Craft L, Lane D, Martin LW, 
Chlebowski R. Physical activity and survival in postmenopausal 
women with breast cancer: results from the women’s health ini-
tiative. Cancer Prev Res. 2011;4:522–9.
 108. Bertram LAC, Stefanick ML, Saquib N, Natarajan L, Patterson 
RE, Bardwell W, Flatt SW, Newman VA, Rock CL, Thomson 
CA, Pierce JP. Physical activity, additional breast cancer events, 
and mortality among early-stage breast cancer survivors: findings 
from the WHEL Study. Cancer Causes Control. 2011;22:427–35.
 109. Bradshaw PT, Ibrahim JG, Khankari N, Cleveland RJ, Abraham-
son PE, Stevens J, Satia JA, Teitelbaum SL, Neugut AI, Gammon 
MD. Post-diagnosis physical activity and survival after breast 
cancer diagnosis: the Long Island Breast Cancer Study. Breast 
Cancer Res Treat. 2014;145:735–42.
 110. Walter V, Jansen L, Knebel P, Chang-Claude J, Hoffmeister M, 
Brenner H. Physical activity and survival of colorectal cancer 
patients: population-based study from Germany. Int J Cancer. 
2017;140:1985–97.
 111. Arem H, Pfeiffer RM, Engels EA, Alfano CM, Hollenbeck A, 
Park Y, Matthews CE. Pre- and postdiagnosis physical activity, 
television viewing, and mortality among patients with colorec-
tal cancer in the National Institutes of Health—AARP diet and 
health study. J Clin Oncol. 2015;33:180–8.
Clinical and Translational Oncology 
1 3
 112. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan 
JA, Colditz GA, Fuchs CS. Physical activity and survival after 
colorectal cancer diagnosis. J Clin Oncol. 2006;24:3527–34.
 113. van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, 
Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza 
D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, 
Ng K, Meyerhardt JA. Association of survival with adherence to 
the american cancer society nutrition and physical activity guide-
lines for cancer survivors after colon cancer diagnosis. JAMA 
Oncol. 2018;4:783–90.
 114. Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. 
Associations of recreational physical activity and leisure time 
spent sitting with colorectal cancer survival. J Clin Oncol. 
2013;31:876–85.
 115. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, 
Chan JM. Physical activity after diagnosis and risk of prostate 
cancer progression: data from the cancer of the prostate strategic 
urologic research endeavor. Cancer Res. 2011;71:3889–95.
 116. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor 
SE, Courneya KS. Physical activity and survival after prostate 
cancer. Eur Urol. 2016;70:576–85.
 117. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical 
activity and survival after prostate cancer diagnosis in the health 
professionals follow-up study. J Clin Oncol. 2011;29:726–32.
 118. Liss M, Natarajan L, Hasan A, Noguchi JL, White M, Parsons 
JK. Physical activity decreases kidney cancer mortality. Curr 
Urol. 2017;10:193–8.
 119. Sloan JA, Cheville AL, Liu H, Novotny PJ, Wampfler JA, Garces 
YI, Clark MM, Yang P. Impact of self-reported physical activ-
ity and health promotion behaviors on lung cancer survivorship. 
Health Qual Outcomes. 2016;14:66.
 120. Wang L, Wang C, Wang J, Huang X, Cheng Y. Longitudinal, 
observational study on associations between postoperative 
nutritional vitamin D supplementation and clinical outcomes in 
esophageal cancer patients undergoing esophagectomy. Sci Rep. 
2016;6:1572–81.
 121. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, 
McTiernan A, Alfano CM. Physical activity, biomarkers, and 
disease outcomes in cancer survivors: a systematic review. J Natl 
Cancer Inst. 2012;104:815–40.
 122. Gunnell AS, Joyce S, Tomlin S, Taaffe DR, Cormie P, New-
ton RU, Joseph D, Spry N, Einarsdóttir K, Galvão DA. Physical 
activity and survival among long-term cancer survivor and non-
cancer cohorts. Front Public Health. 2017;5:19.
 123. Li T, Wei S, Shi Y, Pang S, Qin Q, Yin J, Deng Y, Chen Q, Wei 
S, Nie S, Liu L. The dose–response effect of physical activity on 
cancer mortality: findings from 71 prospective cohort studies. Br 
J Sports Med. 2016;50:339–45.
 124. Schmid D, Leitzmann MF. Association between physical activ-
ity and mortality among breast cancer and colorectal cancer 
survivors: a systematic review and meta-analysis. Ann Oncol. 
2014;25:1293–311.
 125. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, Gib-
son T, Armenian SH, Nilsen TS, Oeffinger KC, Ness KK, Adams 
SC, Robison LL, Armstrong GT, Jones LW. Association of exer-
cise with mortality in adult survivors of childhood cancer. JAMA 
Oncol. 2018;4:1352–8.
 126. Beasley JM, Kwan ML, Chen WY, Weltzien EK, Kroenke CH, 
Lu W, Nechuta SJ, Cadmus-Bertram L, Patterson RE, Sternfeld 
B, Shu X-O, Pierce JP, Caan BJ. Meeting the physical activity 
guidelines and survival after breast cancer: findings from the 
after breast cancer pooling project. Breast Cancer Res Treat. 
2012;131:637–43.
 127. Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat 
RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, 
Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. 
Impact of physical activity after cancer diagnosis on survival 
in patients with recurrent colon cancer: findings from CALGB 
89803/alliance. Clin Colorectal Cancer. 2013;12:233–8.
 128. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, 
Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky 
RL, Fuchs CS. Impact of physical activity on cancer recurrence 
and survival in patients with stage III colon cancer: findings from 
CALGB 89803. J Clin Oncol. 2006;24:3535–41.
 129. Haykowsky MJ, Scott JM, Hudson K, Denduluri N. Lifestyle 
interventions to improve cardiorespiratory fitness and reduce 
breast cancer recurrence. Am Soc Clin Oncol Educ Book. 
2017;37:57–64.
 130. Casla S, Hojman P, Márquez-Rodas I, López-Tarruella S, Jerez 
Y, Barakat R, Martín M. Running away from side effects: physi-
cal exercise as a complementary intervention for breast cancer 
patients. Clin Transl Oncol. 2015;17:180–96.
 131. Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu 
O, Gotay CC, Snyder C. Exercise interventions on health-related 
quality of life for cancer survivors. Cochrane Database Syst Rev. 
2012. https ://doi.org/10.1002/14651 858.cd007 566.pub2.
 132. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, 
Topaloglu O. Exercise interventions on health-related quality of 
life for people with cancer during active treatment. Cochrane 
Database Syst Rev. 2012. https ://doi.org/10.1002/14651 858.
cd008 465.pub2.
 133. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, 
GalvÃO DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia 
A, Schneider CM, Von Gruenigen VE, Schwartz AL. American 
college of sports medicine roundtable on exercise guidelines for 
cancer survivors. Med Sci Sports Exerc. 2010;42:1409–26.
 134. Jones LW, Eves ND, Peddle CJ, Courneya KS, Haykowsky M, 
Kumar V, Winton TW, Reiman T. Effects of presurgical exer-
cise training on systemic inflammatory markers among patients 
with malignant lung lesions. Appl Physiol Nutr Metabol. 
2009;34:197–202.
 135. Ligibel JA, Irwin M, Dillon D, Barry W, Giobbie-Hurder A, 
Frank E, Winer EP, McTiernan A, Cornwell M, Pun M, Brown 
M, Jeselsohn R. Impact of pre-operative exercise on breast can-
cer gene expresision. In: Proceedings of the thirty-ninth annual 
CTRC–AACR San Antonio breast cancer symposium. San Anto-
nio: American Association for Cancer Research; 2017. p. 77.
 136. Furmaniak AC, Menig M, Markes MH. Exercise for women 
receiving adjuvant therapy for breast cancer. Cochrane Database 
Syst Rev. 2016;9:CD005001.
 137. Loughney L, West MA, Kemp GJ, Grocott MPW, Jack S. Exer-
cise intervention in people with cancer undergoing neoadjuvant 
cancer treatment and surgery: a systematic review. Eur J Surg 
Oncol. 2016;42:28–38.
 138. Loughney L, West MA, Kemp GJ, Grocott MPW, Jack S. Exer-
cise intervention in people with cancer undergoing adjuvant can-
cer treatment following surgery: a systematic review. Eur J Surg 
Oncol. 2015;41:1590–602.
 139. Beaudry RI, Liang Y, Boyton ST, Tucker WJ, Brothers RM, Dan-
iel KM, Rao R, Haykowsky MJ. Meta-analysis of exercise train-
ing on vascular endothelial function in cancer survivors. Integr 
Cancer Ther. 2018;17:192–9.
 140. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, 
King AC, Macera CA, Castaneda-Sceppa C. Physical activ-
ity and public health in older adults. Med Sci Sports Exerc. 
2007;39:1435–45.
 141. Turner RR, Steed L, Quirk H, Greasley RU, Saxton JM, Taylor 
SJC, Rosario DJ, Thaha MA, Bourke L. Interventions for promot-
ing habitual exercise in people living with and beyond cancer. 
Cochrane Database Syst Rev. 2018;9:CD010192.
 Clinical and Translational Oncology
1 3
 142. Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, 
Tonorezos E, Soares-Miranda L, Sklar CA, Douglas PS, Robi-
son LL, Oeffinger KC. Exercise and risk of major cardiovascu-
lar events in adult survivors of childhood hodgkin lymphoma: a 
report from the childhood cancer survivor study. J Clin Oncol. 
2014;32:3643–50.
 143. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones 
LW. A framework for prescription in exercise-oncology research. 
J Cachexia Sarcopenia Muscle. 2015;6:115–24.
 144. Padilha CS, Marinello PC, Galvão DA, Newton RU, Borges 
FH, Frajacomo F, Deminice R. Evaluation of resistance training 
to improve muscular strength and body composition in cancer 
patients undergoing neoadjuvant and adjuvant therapy: a meta-
analysis. J Cancer Surviv. 2017;11:339–49.
 145. Jones LW, Courneya KS, Vallance JKH, Ladha AB, Mant MJ, 
Belch AR, Stewart DA, Reiman T. Association between exercise 
and quality of life in multiple myeloma cancer survivors. Support 
Care Cancer. 2004;12:780–8.
 146. Mills RC. Breast cancer survivors, common markers of inflam-
mation, and exercise: a narrative review. Breast Cancer Basic 
Clin Res. 2017;11:117822341774397.
 147. Gil-Rey E, Quevedo-Jerez K, Maldonado-Martin S, Herrero-
Román F. Exercise intensity guidelines for cancer survi-
vors: a comparison with reference values. Int J Sports Med. 
2014;35:e1–9.
 148. Toohey K, Pumpa K, McKune A, Cooke J, Semple S. High-
intensity exercise interventions in cancer survivors: a systematic 
review exploring the impact on health outcomes. J Cancer Res 
Clin Oncol. 2018;144:1–12.
 149. National Academies of Sciences EM, Health and Medicine Divi-
sion. Board on health care services, national cancer policy forum. 
Incorporating weight management and physical activity through-
out the cancer care continuum. In: Proceedings of a workshop. 
Washington, DC: National Academies Press; 2018.
 150. Tudor-Locke C, Bassett DR. How many steps/day are enough? 
Sports Med. 2004;34:1–8.
 151. Chen X, Lu W, Zheng W, Gu K, Matthews CE, Chen Z, Zheng Y, 
Shu XO. Exercise after diagnosis of breast cancer in association 
with survival. Cancer Prev Res. 2011;4:1409–18.
 152. Carayol M, Bernard P, Boiché J, Riou F, Mercier B, Cousson-
Gélie F, Romain AJ, Delpierre C, Ninot G. Psychological 
effect of exercise in women with breast cancer receiving adju-
vant therapy: what is the optimal dose needed? Ann Oncol. 
2013;24:291–300.
 153. Valle C. Enhancing benefits of exercise for the survivor using 
emerging technology. In: ASCO Annual Meeting. Chicago; 201.
 154. Joyner MJ, Sanchis-Gomar F, Lucia A. Exercise medicine educa-
tion should be expanded. Br J Sports Med. 2017;51:625–6.
 155. McDermott LA, Murphy MH, McNeilly AM, Rankin JP, Gracey 
JH. Biological markers as an outcome measure of exercise in 
cancer rehabilitation: a systematic review. J Cancer Res Ther. 
2018;14:267–77.
 156. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, 
Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer 
survivors: consensus statement from international multidiscipli-
nary roundtable. Med Sci Sports Exerc. 2019;51:2375–90.
 157. Jones LW, Peddle CJ, Eves ND, Haykowsky MJ, Courneya KS, 
Mackey JR, et al. Effects of presurgical exercise training on car-
diorespiratory fitness among patients undergoing thoracic sur-
gery for malignant lung lesions. Cancer. 2007;110:590–8.
 158. Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, 
Quist M, et al. Prognostic significance of functional capacity and 
exercise behavior in patients with metastatic non-small cell lung 
cancer. Lung Cancer. 2012;76:248–52.
 159. Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, 
Monninkhof EM, Backx F, et al. Effects of an 18-week exercise 
programme started early during breast cancer treatment: a ran-
domised controlled trial. BMC Med. 2015;13:121.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
